Trial reportAnnals of oncology : official journal of the European Society for Medical Oncology2010
Serious pulmonary toxicity in patients with Hodgkin's lymphoma with SGN-30, gemcitabine, vinorelbine, and liposomal doxorubicin is associated with an FcγRIIIa-158 V/F polymorphism.
Trial report in Annals of oncology : official journal of the European Society for Medical Oncology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 56 citations in OpenAlex.
- A stochastically curtailed two-arm randomised phase II trial design for binary outcomes.Pharmaceutical statistics · 2021Trial
- Brentuximab vedotin with gemcitabine for paediatric and young adult patients with relapsed or refractory Hodgkin's lymphoma (AHOD1221): a Children's Oncology Group, multicentre single-arm, phase 1-2 trial.The Lancet. Oncology · 2018Trial
- Advances in targeted therapy for malignant lymphoma.Signal transduction and targeted therapy · 2020Review
- Novel agents and immune invasion in Hodgkin lymphoma.Hematology. American Society of Hematology. Education Program · 2019Review
- CD30 and CD30-Targeted Therapies in Hodgkin Lymphoma and Other B cell Lymphomas.Current hematologic malignancy reports · 2016Review
- Article
- Role of CD30 targeting in malignant lymphoma.Current treatment options in oncology · 2014Review
- Managing Hodgkin lymphoma relapsing after autologous hematopoietic cell transplantation: a not-so-good cancer after all!Bone marrow transplantation · 2014Review
- Customized targeted therapy in Hodgkin lymphoma: hype or hope?Hematology/oncology clinics of North America · 2014Review
- Digging up the human genome: current progress in deciphering adverse drug reactions.BioMed research international · 2014Review
- New strategies in Hodgkin lymphoma: better risk profiling and novel treatments.Clinical cancer research : an official journal of the American Association for Cancer Research · 2013Review
- Clinical targeting of the TNF and TNFR superfamilies.Nature reviews. Drug discovery · 2013Review
- Article
- Brentuximab Vedotin in CD30+ Lymphomas.Biologics in therapy · 2013Review
- Treatment challenges in the management of relapsed or refractory non-Hodgkin's lymphoma - novel and emerging therapies.Cancer management and research · 2013Review
- Where does brentuximab vedotin fit into the management of patients with Hodgkin lymphoma?Current hematologic malignancy reports · 2012Review
- Emerging Pharmacotherapy for Relapsed or Refractory Hodgkin's Lymphoma: Focus on Brentuximab Vedotin.Clinical Medicine Insights. Oncology · 2012Article
- Hodgkin's lymphoma therapy: past, present, and future.Expert opinion on pharmacotherapy · 2010Review
- Anti-CD30 Antibodies for Hodgkin lymphoma.Current hematologic malignancy reports · 2010Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 7 institutions in 1 country.
Funding
Abstract
backgroundBased on in vitro synergistic cytotoxicity when anti-CD30 antibodies are combined with gemcitabine, the Cancer and Leukemia Group B conducted a double-blind, randomized, phase II trial of SGN-30 with gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD) in patients with relapsed Hodgkin's lymphoma. PATIENTS AND
methodsIn part 1 of the trial, 16 patients received SGN-30 with GVD to assess the safety of the combination. In part 2, patients were randomly allocated to SGN-30 (n = 7) or placebo (n = 7) with GVD to determine overall response rate (ORR).
resultsORR in all 30 patients was 63% (65% with SGN-30 plus GVD, n = 23, and 57% with placebo plus GVD, n = 7). Median event-free survival was 9.0 months, with no difference between the two arms. Grades 3-5 pneumonitis occurred in five patients receiving SGN-30 and GVD, leading to premature closure of the trial. All five patients with pulmonary toxicity had a V/F polymorphism in the FcγRIIIa gene (P = 0.008).
conclusionsTogether with historical data demonstrating a 2% incidence of pulmonary events with GVD, these results indicate that SGN-30 cannot safely be administered concurrently. The risk of pneumonitis with SGN-30 and GVD is greatest in patients with an FcγRIIIa V/F polymorphism.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.